PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for September 28, 2007 Subscribe to this News Feed    
 

Investigators to Meet at Summit to Advance Clinical Research for Spinal Muscular Atrophy

With the recent introduction of SMA legislation in both the U.S. House of Representatives and the U.S. Senate to create a national clinical trials network for spinal muscular atrophy (SMA), the leading advocacy organizations are hosting a two-day summit to work toward reducing or eliminating barriers to development of the drugs that would be tested in that network.

Bethesda, MD (PRWEB) September 28, 2007 -- With the recent introduction of SMA legislation in both the U.S. House of Representatives and the U.S. Senate to create a national clinical trials network for spinal muscular atrophy (SMA), the leading advocacy organizations are hosting a two-day summit to work toward reducing or eliminating barriers to development of the drugs that would be tested in that network.

The SMA Summit on Drug Development, which is being held on September 28 and 29 at the Hyatt Regency Bethesda, in Bethesda, MD, will include representatives from the pharmaceutical industry, family support groups, clinicians and government. These stakeholders in the clinical research process will discuss infrastructure, regulatory, and community support needs for evaluating treatments in development. The goal is to speed the development and approval of drugs designed to treat SMA, for which there is currently no approved treatment.

Spinal muscular atrophy is a neuromuscular disease that kills more children under two than any other genetic disorder. It affects the victim's motor neurons, causing muscle atrophy, loss of strength, disability and premature death due to respiratory complications in the majority of affected children.

Both the bill and the drug summit were conceived and implemented through the collaboration of SMA organizations and other parties that have an interest in accelerating a treatment and cure for this disease. These efforts are in anticipation of clinical trials to test new drug treatments for SMA.

Media Contacts:

Lenna Scott
Families of SMA
http://www.fsma.org
(847) 975-4171
lenna(at)fsma.org

Steve Mullen
Fight SMA
http://www.fightsma.org
(804) 382-0017
steve(at)endgamepr.com

Cynthia Joyce
SMA Foundation
http://www.smafoundation.org
(646) 253-7102
cjoyce(at)smafoundation.org

Bob Mackle
MDA
http://www.mdausa.org
(520) 529-5317
bobmackle(at)mdausa.org

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3F1YS1GYWx1LUNyYXMtTWFnbi1UaGlyLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


Other Releases by this Member
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION
Steve Mullen
EndGame Public Relations
804-382-0017
Email us Here
ATTACHED FILES

Fight SMA

Fight SMA

SMA Foundation

SMA Foundation

Families of SMA

Families of SMA

MDA

MDA

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.